Fangxia Zou

机构：Yantai University, Ministry of Education, Luye Pharma (China), Systèmes avancés de délivrance de principes actifs, Dali University · ORCID：0000-0001-9356-5614

发表论文 29 篇 · 总被引 198 次 · h-index 9

代表论文

• Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective (2018 · Journal of Medicinal Chemistry · 被引 31)
• PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations (2019 · Scientific Reports · 被引 20)
• PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer (2020 · Toxicology and Applied Pharmacology · 被引 19)
• Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening (2017 · Bioorganic & Medicinal Chemistry Letters · 被引 16)
• Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1 (2017 · Bioorganic & Medicinal Chemistry · 被引 15)
• Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT2A receptor antagonists/inverse agonists (2022 · European Journal of Medicinal Chemistry · 被引 13)